Jyanwei Liu
Overview
Explore the profile of Jyanwei Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vendeville S, Amblard F, Bassit L, Beigelman L, Blatt L, Chen X, et al.
J Med Chem
. 2024 Nov;
67(23):21126-21142.
PMID: 39575679
Chronic hepatitis B (CHB) represents a significant unmet medical need with few options beyond lifelong treatment with nucleoside analogues, which rarely leads to a functional cure. Novel agents that reduce...
2.
Rajagopalan R, Pan L, Schaefer C, Nicholas J, Lim S, Misialek S, et al.
Antimicrob Agents Chemother
. 2016 Nov;
61(1).
PMID: 27795376
The current paradigm for the treatment of chronic hepatitis C virus (HCV) infection involves combinations of agents that act directly on steps of the HCV life cycle. Here we report...
3.
Deval J, Hong J, Wang G, Taylor J, Smith L, Fung A, et al.
PLoS Pathog
. 2015 Jun;
11(6):e1004995.
PMID: 26098424
Respiratory syncytial virus (RSV) causes severe lower respiratory tract infections, yet no vaccines or effective therapeutics are available. ALS-8176 is a first-in-class nucleoside analog prodrug effective in RSV-infected adult volunteers,...
4.
Wang G, Deval J, Hong J, Dyatkina N, Prhavc M, Taylor J, et al.
J Med Chem
. 2015 Feb;
58(4):1862-78.
PMID: 25667954
Respiratory syncytial virus (RSV) is a leading pathogen of childhood and is associated with significant morbidity and mortality. To date, ribavirin is the only approved small molecule drug, which has...